Mary J. Laughlin, M.D. established the Cleveland Cord Blood Center (CCBC) in 2008 in recognition of the growing role of stem-cell rich umbilical cord blood for transplantation in patients with life threatening disorders such as leukemia, lymphoma and immune system disorders. Dr. Laughlin, who performed one of the world’s first successful umbilical cord blood stem cell transplants on an adult leukemia patient in 1995, launched the public cord blood bank with the commitment to serve the unmet needs of a diverse population for whom well-matched stem cell grafts are not generally available in the adult donor registry.
In the rapidly advancing cellular therapy industry, Cleveland Cord Blood Center’s new Cell Therapy Incubator (CTI) is designed to help move innovative cellular therapy products from Research & Development to FDA approval. Services are designed to help developers of cell-based therapies in regenerative medicine reach the critical milestones needed to accomplish clinical proof of concept for safety and efficacy of dosing, dose formulation and regimens.